Sucampo Adds New Member To Board
This article was originally published in Scrip
Sucampo Pharmaceuticals, Inc. has named Timothy P. Walbert to its board of directors. Currently, Walbert is chair, president and CEO of Horizon Pharma Plc. and prior to this he was CEO, president and director of IDM Pharma, Inc. which was acquired by Takeda. Walbert has also previously served as executive vice-president of commercial operations at NeoPharm, Inc.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.